Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1479-1483

  Erdogan, Bulent ^a   Turkmen, Esma ^a   Uzunoglu, Sernaz ^a   Tanriverdi, Ozgur ^b   Cicin, Irfan ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

Author keywords

Disease control; Pancreaticobiliary adenocarcinoma; Performance status; Second line chemotherapy

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROPYRIMIDINE; GEMCITABINE; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGE; AGED; ARTICLE; BILE DUCT CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREATICOBILIARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84885708799     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13269     Document Type: Article

References (18)

1. Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-2413. (Pubitemid 27251144)
2. Colucci G, Labianca R, Di Costanzo F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-1651.
3. Cunningham D, Chau I, Stocken DD, et al.: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009; 27:5513-5518.
4. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-1825.
5. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-1966. (Pubitemid 46972777)
6. Valle J, Wasan H, Palmer DH, et al.: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273-1281.
7. Nehls O, Oettle H, Hartmann JT, et al.: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98:309-315. (Pubitemid 351161262)
8. Kim TW, Chang HM, Rang HJ, et al.: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14:1115-1120. (Pubitemid 36950177)
9. Boeck S, Wilkowski R, Bruns CL, et al.: Oral capecitabine in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-227. (Pubitemid 351630054)
10. Androulakis N, Syrigos K, Polyzos A, et al.: Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 2005; 23:9-12. (Pubitemid 40344194)
11. Gebbia V, Maiello E, Giuliani F, et al.: Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX-4 regimen in clinical practice. Ann Oncol 2007; 18(Suppl. 6):124-127.
12. Berk V, Ozdemir N, Ozkan M, et al.: XELOX versus FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 2012; 59(120):2635-2639.
13. Xiong HQ, Varadhachary GR, Blais JC, et al.: A phase II trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046-2052.
14. Heinemann V, Phillip PA, Pelzer U: Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastro-intest Cancer Res 2009; 3(Suppl. 2):43-47.
15. Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47:1676-1681.
16. Custodio A, Puente J, Sastre J, et al.: Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions. Cancer Treat Rev 2009; 35:676-684.
17. Pelzer U, Kubica K, Stieler J, et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study, [abstract] J Clin Oncol 2008; 26 Suppl 1 Abstract 4508.
18. Zhang YD, Yang Q, Jiang ZM, et al.: Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy JOP 2011; 12:131-137.